Login / Signup

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours.

Juan Martín-LiberalAntoine HollebecquePhilippe AftimosChristiane JungelsPatricia Martin-RomanoJordi RodonJill Dolores KremerWei ZhangJohanna Bendell
Published in: British journal of cancer (2020)
LY3127804 monotherapy and its combination with ramucirumab are well tolerated. LY3127804 20 mg/kg was the recommended Phase 2 dose.
Keyphrases
  • open label
  • combination therapy
  • endothelial cells
  • clinical trial
  • induced pluripotent stem cells
  • study protocol
  • randomized controlled trial
  • pluripotent stem cells